SG11202102432TA - Immunomodulators, compositions and methods there of - Google Patents

Immunomodulators, compositions and methods there of

Info

Publication number
SG11202102432TA
SG11202102432TA SG11202102432TA SG11202102432TA SG11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA
Authority
SG
Singapore
Prior art keywords
immunomodulators
compositions
methods
Prior art date
Application number
SG11202102432TA
Inventor
Yiqian Wang
Yao Zhang
Bang Fu
Jiabing Wang
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of SG11202102432TA publication Critical patent/SG11202102432TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57Aryl or substituted aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
SG11202102432TA 2018-09-13 2019-09-12 Immunomodulators, compositions and methods there of SG11202102432TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018105582 2018-09-13
PCT/CN2019/105685 WO2020052650A1 (en) 2018-09-13 2019-09-12 Immunomodulators, compositions and methods there of

Publications (1)

Publication Number Publication Date
SG11202102432TA true SG11202102432TA (en) 2021-04-29

Family

ID=69776767

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102432TA SG11202102432TA (en) 2018-09-13 2019-09-12 Immunomodulators, compositions and methods there of

Country Status (11)

Country Link
US (1) US20220041583A1 (en)
EP (1) EP3849972A4 (en)
JP (1) JP7453963B2 (en)
KR (1) KR20210061359A (en)
CN (1) CN112654617A (en)
AU (1) AU2019339703A1 (en)
CA (1) CA3112286A1 (en)
EA (1) EA202190766A1 (en)
IL (1) IL281164A (en)
SG (1) SG11202102432TA (en)
WO (1) WO2020052650A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210300909A1 (en) * 2018-07-19 2021-09-30 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3377488B1 (en) * 2015-11-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
JP2019530732A (en) * 2016-08-03 2019-10-24 アライジング・インターナショナル・インコーポレイテッドArising International, Inc. Symmetric or semi-symmetrical compounds useful as immune modulators
KR102599339B1 (en) * 2016-12-20 2023-11-08 브리스톨-마이어스 스큅 컴퍼니 Compounds useful as immunomodulators
MD3558990T2 (en) 2016-12-22 2023-02-28 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as PD-L1 internalization inducers
JP7101678B2 (en) * 2016-12-22 2022-07-15 インサイト・コーポレイション Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
JOP20180040A1 (en) * 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
AU2019245288C1 (en) * 2018-03-30 2024-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20210300909A1 (en) 2018-07-19 2021-09-30 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
AU2020214404A1 (en) * 2019-01-31 2021-09-23 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof

Also Published As

Publication number Publication date
EP3849972A4 (en) 2022-06-01
CA3112286A1 (en) 2020-03-19
IL281164A (en) 2021-04-29
CN112654617A (en) 2021-04-13
EP3849972A1 (en) 2021-07-21
US20220041583A1 (en) 2022-02-10
EA202190766A1 (en) 2021-06-17
WO2020052650A1 (en) 2020-03-19
KR20210061359A (en) 2021-05-27
JP7453963B2 (en) 2024-03-21
AU2019339703A1 (en) 2021-04-08
JP2022511303A (en) 2022-01-31

Similar Documents

Publication Publication Date Title
IL285215A (en) Immunomodulators, compositions and methods thereof
EP3774750A4 (en) Immunomodulators, compositions and methods thereof
IL265045B1 (en) Pd-1 homing endonuclease variants, compositions, and methods of use
ZA202007839B (en) Polymerases, compositions, and methods of use
ZA202007838B (en) Polymerases, compositions, and methods of use
IL280134A (en) Anti-cd112r compositions and methods
IL268970A (en) Novel compositions and methods
IL270776A (en) Cblb endonuclease variants, compositions, and methods of use
GB201807325D0 (en) Compositions and methods
EP3526334A4 (en) Tgfbetar2 endonuclease variants, compositions, and methods of use
GB202201861D0 (en) Novel methods and compositions
EP3504335A4 (en) Tim3 homing endonuclease variants, compositions, and methods of use
IL280414A (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
SG11202104448WA (en) Compositions and methods
GB2576614B (en) Compositions, uses and methods
IL277786A (en) Aav compositions, methods of making and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
GB201804163D0 (en) Uses, compositions and methods
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
GB201817444D0 (en) Methods and compositions
ZA202004533B (en) Skin-brightening compositions and methods
IL281164A (en) Immunomodulators, compositions and methods there of
GB201819987D0 (en) Methods and compositions
ZA202104192B (en) Mmpl3 inhibitors, compositions and uses thereof